Document is current
Any future updates will be listed below
-
Authors
Dingens, Adam S. https://orcid.org/0000-0001-9603-9409
Crawford, Katharine H. D.
Adler, Amanda
Steele, Sarah L.
Lacombe, Kirsten
Eguia, Rachel
Amanat, Fatima https://orcid.org/0000-0002-8029-8227
Walls, Alexandra C.
Wolf, Caitlin R.
Murphy, Michael
Pettie, Deleah https://orcid.org/0000-0002-5477-7195
Carter, Lauren
Qin, Xuan
King, Neil P.
Veesler, David https://orcid.org/0000-0002-6019-8675
Krammer, Florian https://orcid.org/0000-0003-4121-776X
Dickerson, Jane A.
Chu, Helen Y.
Englund, Janet A.
Bloom, Jesse D. https://orcid.org/0000-0003-1267-3408
-
Funding
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R01AI140891)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (HHSN272201700059C)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (F30AI149928)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (HHSN272201400008C)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (75N93019C00051)
Bill and Melinda Gates Foundation (OPP1156262)
Howard Hughes Medical Institute
- License Information
-
More Information
Article History
Received: 26 June 2020
Accepted: 7 August 2020
First Online: 1 September 2020
Competing interests
: H.Y.C. is a consultant for Merck and Glaxo Smith Kline and receives research funding from Sanofi Pasteur, outside of the submitted work. N.P.K. is a co-founder, shareholder, and chair of the scientific advisory board of Icosavax, Inc. Mount Sinai has licensed serological assays to commercial entities and has filed for patent protection for serological assays. J.A.E. is a consultant for Sanofi Pasteur and Meissa Vaccines. The remaining authors declare no competing interests.
